ReviewBMB reports2026
Differential regulation of type 2 immunity by glucocorticoids.
Review in BMB reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoids (GCs) are steroid hormones that are commonly utilized in clinical practice due to their immunosuppressive properties. While GCs are commonly understood to diminish various aspects of the immune response, there is evidence suggesting that they may, under certain conditions, enhance immune responses, particularly within the realm of type 2 immunity. In this mini review, we delineate the current understanding of how GCs differentially affect immune responses related to type 2 immunity, including both in vivo and in vitro-such as Th2 (T helper type 2) cell differentiation, regulatory T cell functions, immunoglobulin E production by B cells, and the roles of myeloid cells like dendritic cells, mast cells, eosinophils, and basophils. Furthermore, we probe the molecular mechanisms by which GCs selectively influence these cell types, and discuss how these insights enhance our basic understanding of GC-driven immune regulation. Unraveling these intricate, context-dependent effects could inform the development of more precise and efficacious GC-based treatments, while reducing adverse outcomes associated with Th1/Th2 imbalance, including heightened infection risks and exacerbation of allergic responses. [BMB Reports 2026; 59(2): 101-111].
Indexed as
Identifiers
40716956PMC12936599What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.